Anhui Zhongke Tuoran Pharmaceutical Research

Anhui Zhongke Tuoran Pharmaceutical Research is a clinical-stage biopharmaceutical company headquartered in Hefei, China, focused on developing innovative small molecule drugs for oncology. The company was founded as a spin-off from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, utilizing the research team's expertise in medicinal chemistry and pharmacology. Its core technology platform integrates structure-based drug design with high-throughput screening to identify highly selective kinase inhibitors. The lead program, TR-001, is a potent pan-FGFR inhibitor currently in Phase 1/2 clinical trials for patients with advanced solid tumors, including cholangiocarcinoma and urothelial carcinoma. Zhongke Tuoran aims to provide precision medicine solutions for cancer patients with specific genetic alterations. The company is supported by regional investment groups and maintains strong ties with academic research institutions.